A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2

Kai B. Kaufmann, Albert Gründer, Tobias Hadlich, Julius Wehrle, Monika Gothwal, Ruzhica Bogeska, Thalia S. Seeger, Sarah Kayser, Kien Binh Pham, Jonas S. Jutzi, Lucas Ganzenmüller, Doris Steinemann, Brigitte Schlegelberger, Julia M. Wagner, Manfred Jung, Britta Will, Ulrich G. Steidl, Konrad Aumann, Martin Werner, Thomas Günther & 3 others Roland Schüle, Alessandro Rambaldi, Heike L. Pahl

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The molecular pathophysiology of myeloproliferative neoplasms (MPNs) remains poorly understood. Based on the observation that the transcription factor NF-E2 is often overexpressed in MPN patients, independent of the presence of other molecular aberrations, we generated mice expressing an NF-E2 transgene in hematopoietic cells. These mice exhibit many features of MPNs, including thrombocytosis, leukocytosis, Epo-independent colony formation, characteristic bone marrow histology, expansion of stem and progenitor compartments, and spontaneous transformation to acute myeloid leukemia. The MPN phenotype is transplantable to secondary recipient mice. NF-E2 can alter histone modifications, and NF-E2 transgenic mice show hypoacetylation of histone H3. Treatment of mice with the histone deacetylase inhibitor (HDAC-I) vorinostat restored physiological levels of histone H3 acetylation, decreased NF-E2 expression, and normalized platelet numbers. Similarly, MPN patients treated with an HDAC-I exhibited a decrease in NF-E2 expression. These data establish a role for NF-E2 in the pathophysiology of MPNs and provide a molecular rationale for investigating epigenetic alterations as novel targets for rationally designed MPN therapies.

Original languageEnglish (US)
Pages (from-to)35-50
Number of pages16
JournalJournal of Experimental Medicine
Volume209
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

NF-E2 Transcription Factor
Myeloproliferative Disorders
Neoplasms
Histone Deacetylase Inhibitors
Histones
Histone Code
Thrombocytosis
Leukocytosis
Acetylation
Platelet Count
Transgenes
Acute Myeloid Leukemia
Epigenomics
Transgenic Mice
Histology
Bone Marrow
Phenotype

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Kaufmann, K. B., Gründer, A., Hadlich, T., Wehrle, J., Gothwal, M., Bogeska, R., ... Pahl, H. L. (2012). A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. Journal of Experimental Medicine, 209(1), 35-50. https://doi.org/10.1084/jem.20110540

A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. / Kaufmann, Kai B.; Gründer, Albert; Hadlich, Tobias; Wehrle, Julius; Gothwal, Monika; Bogeska, Ruzhica; Seeger, Thalia S.; Kayser, Sarah; Pham, Kien Binh; Jutzi, Jonas S.; Ganzenmüller, Lucas; Steinemann, Doris; Schlegelberger, Brigitte; Wagner, Julia M.; Jung, Manfred; Will, Britta; Steidl, Ulrich G.; Aumann, Konrad; Werner, Martin; Günther, Thomas; Schüle, Roland; Rambaldi, Alessandro; Pahl, Heike L.

In: Journal of Experimental Medicine, Vol. 209, No. 1, 01.2012, p. 35-50.

Research output: Contribution to journalArticle

Kaufmann, KB, Gründer, A, Hadlich, T, Wehrle, J, Gothwal, M, Bogeska, R, Seeger, TS, Kayser, S, Pham, KB, Jutzi, JS, Ganzenmüller, L, Steinemann, D, Schlegelberger, B, Wagner, JM, Jung, M, Will, B, Steidl, UG, Aumann, K, Werner, M, Günther, T, Schüle, R, Rambaldi, A & Pahl, HL 2012, 'A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2', Journal of Experimental Medicine, vol. 209, no. 1, pp. 35-50. https://doi.org/10.1084/jem.20110540
Kaufmann, Kai B. ; Gründer, Albert ; Hadlich, Tobias ; Wehrle, Julius ; Gothwal, Monika ; Bogeska, Ruzhica ; Seeger, Thalia S. ; Kayser, Sarah ; Pham, Kien Binh ; Jutzi, Jonas S. ; Ganzenmüller, Lucas ; Steinemann, Doris ; Schlegelberger, Brigitte ; Wagner, Julia M. ; Jung, Manfred ; Will, Britta ; Steidl, Ulrich G. ; Aumann, Konrad ; Werner, Martin ; Günther, Thomas ; Schüle, Roland ; Rambaldi, Alessandro ; Pahl, Heike L. / A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. In: Journal of Experimental Medicine. 2012 ; Vol. 209, No. 1. pp. 35-50.
@article{06f07259777f48489b2e975e25d10f45,
title = "A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2",
abstract = "The molecular pathophysiology of myeloproliferative neoplasms (MPNs) remains poorly understood. Based on the observation that the transcription factor NF-E2 is often overexpressed in MPN patients, independent of the presence of other molecular aberrations, we generated mice expressing an NF-E2 transgene in hematopoietic cells. These mice exhibit many features of MPNs, including thrombocytosis, leukocytosis, Epo-independent colony formation, characteristic bone marrow histology, expansion of stem and progenitor compartments, and spontaneous transformation to acute myeloid leukemia. The MPN phenotype is transplantable to secondary recipient mice. NF-E2 can alter histone modifications, and NF-E2 transgenic mice show hypoacetylation of histone H3. Treatment of mice with the histone deacetylase inhibitor (HDAC-I) vorinostat restored physiological levels of histone H3 acetylation, decreased NF-E2 expression, and normalized platelet numbers. Similarly, MPN patients treated with an HDAC-I exhibited a decrease in NF-E2 expression. These data establish a role for NF-E2 in the pathophysiology of MPNs and provide a molecular rationale for investigating epigenetic alterations as novel targets for rationally designed MPN therapies.",
author = "Kaufmann, {Kai B.} and Albert Gr{\"u}nder and Tobias Hadlich and Julius Wehrle and Monika Gothwal and Ruzhica Bogeska and Seeger, {Thalia S.} and Sarah Kayser and Pham, {Kien Binh} and Jutzi, {Jonas S.} and Lucas Ganzenm{\"u}ller and Doris Steinemann and Brigitte Schlegelberger and Wagner, {Julia M.} and Manfred Jung and Britta Will and Steidl, {Ulrich G.} and Konrad Aumann and Martin Werner and Thomas G{\"u}nther and Roland Sch{\"u}le and Alessandro Rambaldi and Pahl, {Heike L.}",
year = "2012",
month = "1",
doi = "10.1084/jem.20110540",
language = "English (US)",
volume = "209",
pages = "35--50",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "1",

}

TY - JOUR

T1 - A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2

AU - Kaufmann, Kai B.

AU - Gründer, Albert

AU - Hadlich, Tobias

AU - Wehrle, Julius

AU - Gothwal, Monika

AU - Bogeska, Ruzhica

AU - Seeger, Thalia S.

AU - Kayser, Sarah

AU - Pham, Kien Binh

AU - Jutzi, Jonas S.

AU - Ganzenmüller, Lucas

AU - Steinemann, Doris

AU - Schlegelberger, Brigitte

AU - Wagner, Julia M.

AU - Jung, Manfred

AU - Will, Britta

AU - Steidl, Ulrich G.

AU - Aumann, Konrad

AU - Werner, Martin

AU - Günther, Thomas

AU - Schüle, Roland

AU - Rambaldi, Alessandro

AU - Pahl, Heike L.

PY - 2012/1

Y1 - 2012/1

N2 - The molecular pathophysiology of myeloproliferative neoplasms (MPNs) remains poorly understood. Based on the observation that the transcription factor NF-E2 is often overexpressed in MPN patients, independent of the presence of other molecular aberrations, we generated mice expressing an NF-E2 transgene in hematopoietic cells. These mice exhibit many features of MPNs, including thrombocytosis, leukocytosis, Epo-independent colony formation, characteristic bone marrow histology, expansion of stem and progenitor compartments, and spontaneous transformation to acute myeloid leukemia. The MPN phenotype is transplantable to secondary recipient mice. NF-E2 can alter histone modifications, and NF-E2 transgenic mice show hypoacetylation of histone H3. Treatment of mice with the histone deacetylase inhibitor (HDAC-I) vorinostat restored physiological levels of histone H3 acetylation, decreased NF-E2 expression, and normalized platelet numbers. Similarly, MPN patients treated with an HDAC-I exhibited a decrease in NF-E2 expression. These data establish a role for NF-E2 in the pathophysiology of MPNs and provide a molecular rationale for investigating epigenetic alterations as novel targets for rationally designed MPN therapies.

AB - The molecular pathophysiology of myeloproliferative neoplasms (MPNs) remains poorly understood. Based on the observation that the transcription factor NF-E2 is often overexpressed in MPN patients, independent of the presence of other molecular aberrations, we generated mice expressing an NF-E2 transgene in hematopoietic cells. These mice exhibit many features of MPNs, including thrombocytosis, leukocytosis, Epo-independent colony formation, characteristic bone marrow histology, expansion of stem and progenitor compartments, and spontaneous transformation to acute myeloid leukemia. The MPN phenotype is transplantable to secondary recipient mice. NF-E2 can alter histone modifications, and NF-E2 transgenic mice show hypoacetylation of histone H3. Treatment of mice with the histone deacetylase inhibitor (HDAC-I) vorinostat restored physiological levels of histone H3 acetylation, decreased NF-E2 expression, and normalized platelet numbers. Similarly, MPN patients treated with an HDAC-I exhibited a decrease in NF-E2 expression. These data establish a role for NF-E2 in the pathophysiology of MPNs and provide a molecular rationale for investigating epigenetic alterations as novel targets for rationally designed MPN therapies.

UR - http://www.scopus.com/inward/record.url?scp=84856911269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856911269&partnerID=8YFLogxK

U2 - 10.1084/jem.20110540

DO - 10.1084/jem.20110540

M3 - Article

VL - 209

SP - 35

EP - 50

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 1

ER -